<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144718">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02044185</url>
  </required_header>
  <id_info>
    <org_study_id>CMC-SGJ-Lymphoma-LAB-01</org_study_id>
    <nct_id>NCT02044185</nct_id>
  </id_info>
  <brief_title>Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>CHIP-SCT</acronym>
  <official_title>Observational Study for Clinical Implications of HMGB1 (High-mobility Group Protein B1) in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Graft-versus-host disease(aGVDH) after allogeneic hematopoietic stem cell
      transplantation is one of the meaningful issues in aspect of  patient's recovery and
      survival. in recent years, the understanding of the pathology of GVHD is much important to
      prevent or treat aGVHD. HMGB1 is a nuclear protein acts as a transcription factor, but, if
      it was released to the outside of cells by damaged cell or necrotic tissues, it works as
      cytokines for promoter of inflammation and cancers. at this point, there are no reported
      articles about correlation of HMGB1 and aGVHD in human. recently, we have seen excessive
      secretion of serum HMGB1 in mouse model, then base on this results, we will check
      correlation of HMGB1 and aGVHD in human.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. materials 1) inclusion criteria

             1. over 18-year-old

             2. patients with myeloablative conditioning regimen

             3. autologous transplant

             4. patients with confirmation of acute GVHD as over grade II

             5. patients with salvage chemotherapy

                2) exclusion criteria

             1. old age ( over 60-year-old)

             2. patients with reduced intensity stem cell transplantation

        2. method 1) check the serum level of HMGB1, TNF-a, IL-1b, IL-6, Th1, Th2, Th17, FoxP3 on
           7-day before transplant day(D-7), transplant day(D0), 7-day after transplant(D+7),
           D+14, D+21. 2) check the immunohistochemistry level of tissue in diagnosed aGVHD (
           performed sigmoidoscopy and random biopsy of gut is routine process in our center)

        3. analysis 1) student t-test , chi-square test 2) survival analysis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>comparison of serum HMGB1 level before and after diagnosed acute GVHD</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>day 7 before stem cell transplantation(SCT), day 0, day 7, 14 after SCT, and date of diagnosed acute GVHD in all patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum level of immunosuppressive drugs in patients with acute GVHD</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>day 7 before stem cell transplantation(SCT), day 0, day 7, 14 after SCT, and date of diagnosed acute GVHD in all patients.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>tissue IHC stain level of biopsy samples of diagnosed acute GVHD</measure>
    <time_frame>if patients diagnosed with acute GVHD will be performed random biopy of colon or stomach.</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute GVH Disease</condition>
  <arm_group>
    <arm_group_label>high dose chemotherapy</arm_group_label>
    <description>group of using myeloablation regimen, autologous stell cell transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>normal population with health screening</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood serum, biopsy tissue samples of colon
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. patients with bone marrow transplantation of patients with acute leukemia, lymphoma
             in patients group

          2. normal populations in Health Promotion Center in control group
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Inclusion Criteria:

               1. over 18-year-old

               2. patients with myeloablative conditioning regimen

               3. autologous transplant

               4. patients with confirmation of acute GVHD as over grade II

               5. patients with salvage chemotherapy

          2. Exclusion Criteria:

               1. old age ( over 60-year-old)

               2. patients with reduced intensity stem cell transplantation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>seok-goo CHO, M.D,Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>young-woo JEON, bachelor, MD</last_name>
    <phone>821042324067</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul St.Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo-jin KIM</last_name>
      <phone>822225880212</phone>
      <email>irbcumc@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Brennan TV, Lin L, Huang X, Cardona DM, Li Z, Dredge K, Chao NJ, Yang Y. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood. 2012 Oct 4;120(14):2899-908. doi: 10.1182/blood-2011-07-368720. Epub 2012 Jul 3.</citation>
    <PMID>22760779</PMID>
  </reference>
  <reference>
    <citation>Kornblit B, Masmas T, Petersen SL, Madsen HO, Heilmann C, Schejbel L, Sengeløv H, Müller K, Garred P, Vindeløv L. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010 Feb;16(2):239-52. doi: 10.1016/j.bbmt.2009.10.002. Epub 2009 Oct 9.</citation>
    <PMID>19819342</PMID>
  </reference>
  <reference>
    <citation>Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, Pass HI, Gaudino G, Carbone M, Yang H. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012 Jul 1;72(13):3290-301. doi: 10.1158/0008-5472.CAN-11-3481. Epub 2012 May 2.</citation>
    <PMID>22552293</PMID>
  </reference>
  <reference>
    <citation>Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res. 2013 Aug 1;19(15):4046-57. doi: 10.1158/1078-0432.CCR-13-0495. Epub 2013 May 30.</citation>
    <PMID>23723299</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>JEON YOUNG-WOO</investigator_full_name>
    <investigator_title>medical doctor, fellowship</investigator_title>
  </responsible_party>
  <keyword>HMGB1 Protein</keyword>
  <keyword>Graft Versus Host Disease</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
